Shareholders Foundation, Inc.

Graphite Bio, Inc. (NASDAQ:GRPH) Investor Alert: Investigation over Potential Wrongdoing

An investigation on behalf of investors in Graphite Bio, Inc. (NASDAQ:GRPH) shares over potential wrongdoing at Graphite Bio, Inc. was announced and NASDAQ:GRPH stockholders should contact the Shareholders Foundation.

 

San Diego, CA -- (SBWIRE) -- 05/26/2022 -- An investigation on behalf of current long-term investors in shares of Graphite Bio, Inc. (NASDAQ: GRPH) was announced over potential breaches of fiduciary duties by certain officers and directors at Graphite Bio, Inc.

Investors who purchased shares of Graphite Bio, Inc. (NASDAQ: GRPH) and currently hold any of those NASDAQ: GRPH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Graphite Bio, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Francisco, CA based Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States On or around June 25, 2021, Graphite Bio, Inc. conducted its initial public offering ("IPO"), issuing 14 million shares of common stock priced at $17.00 per share.

Then, on March 21, 2022, Graphite Bio, Inc. provided business updates and announcing is fourth quarter and fiscal year 2021 financial results. Among other items, Graphite Bio, Inc. disclosed that the early proof-of-concept data from the Phase 1/2 CEDAR clinical trial for GPH101 in sickle cell disease are now expected in 2023, attributing the delay "to impacts of the recent COVID-19 Omicron variant surge on patients and site resources and operations[.]"

Shares of Graphite Bio, Inc. (NASDAQ: GRPH) declined from $11.30 per share on February 16, 2022, to as low as $2.07 per share on May 25, 2022.

Those who purchased shares of Graphite Bio, Inc. (NASDAQ: GRPH) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.